Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

Objective To investigate the impact of baseline and time‐varying factors on the risk of serious adverse events (SAEs) in patients during long‐term certolizumab pegol (CZP) treatment. Methods Safety data were pooled across 34 CZP clinical trials in rheumatoid arthritis (RA), axial spondyloarthritis (...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Vivian P. Bykerk, Andrew Blauvelt, Jeffrey R. Curtis, Cécile Gaujoux‐Viala, Tore K. Kvien, Kevin Winthrop, Nicola Tilt, Christina Popova, Xavier Mariette, Boulos Haraoui
التنسيق: مقال
اللغة:English
منشور في: Wiley 2021-08-01
سلاسل:ACR Open Rheumatology
الوصول للمادة أونلاين:https://doi.org/10.1002/acr2.11259

مواد مشابهة

مواد مشابهة